A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease
Status:
Completed
Trial end date:
2019-08-22
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK), tolerabilty and
safety of a single dose of ID-085 in subjects with mild, moderate, and severe renal function
impairment compared to healthy subjects